Exelixis (EXEL) Liabilities and Shareholders Equity (2010 - 2026)
Exelixis (EXEL) posted quarterly Liabilities and Shareholders Equity of $2.6 billion for Q2 2026, down 8.59% year-over-year from $2.8 billion in Q2 2025, and down 8.82% quarter-over-quarter from $2.8 billion in Q1 2026.
Exelixis (EXEL) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Exelixis' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $2.6 billion for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity fell 8.59% year-over-year to $2.6 billion; the TTM figure through Apr 2026 stood at $10.9 billion (down 5.02% YoY), while the FY2026 annual figure was $2.8 billion, down 3.5% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $2.6 billion, down from $2.8 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $3.1 billion in Q1 2023, with the low at $2.6 billion in Q2 2026.
- The 5-year median for Liabilities and Shareholders Equity is $2.9 billion (2022), against an average of $2.9 billion.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity grew 21.72% in 2022, then retreated 11.75% in 2024.
- Exelixis' Liabilities and Shareholders Equity stood at $3.1 billion in 2022, then retreated by 4.2% to $2.9 billion in 2023, then gained by 0.61% to $3.0 billion in 2024, then decreased by 4.62% to $2.8 billion in 2025, then decreased by 8.14% to $2.6 billion in 2026.
- Business Quant data shows EXEL's Liabilities and Shareholders Equity at $2.6 billion in Q2 2026, $2.8 billion in Q1 2026, and $2.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 2.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 2.49 Bn |
| Apr 3, 2026 | 2.59 Bn |
| Jan 2, 2026 | 2.84 Bn |
| Oct 3, 2025 | 2.82 Bn |
| Jul 4, 2025 | 2.68 Bn |
| Apr 4, 2025 | 2.84 Bn |
| Jan 3, 2025 | 2.95 Bn |
| Sep 27, 2024 | 2.96 Bn |
| Jun 28, 2024 | 2.77 Bn |
| Mar 29, 2024 | 2.80 Bn |
| Dec 29, 2023 | 2.94 Bn |
| Sep 29, 2023 | 2.98 Bn |
| Jun 30, 2023 | 3.14 Bn |
| Mar 31, 2023 | 3.14 Bn |
| Dec 30, 2022 | 3.07 Bn |
| Sep 30, 2022 | 2.96 Bn |
| Jul 1, 2022 | 2.88 Bn |
| Apr 1, 2022 | 2.65 Bn |
| Dec 31, 2021 | 2.62 Bn |
| Oct 1, 2021 | 2.45 Bn |